3 Works cited FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, accessed February 2, 2026, Semaglutide Shortage Resolved McDermott Will & Schulte, accessed February 2, 2026, GLP-1 Update: Court Backs FDA in Tirzepatide Compounding Case, accessed February 2, 2026, The Return of 503B Compounding of GLP-1 Medications Frier Levitt, accessed February 2, 2026, The Strategic Imperative of Pharmaceutical Competitor Analysis: A Comprehensive Guide for 2026 and Beyond DrugPatentWatch, accessed February 2, 2026, Maximizing ROI on Drug Development by Monitoring Competitive Patent Portfolios, accessed February 2, 2026, Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act FDA, accessed February 2, 2026, GLP-1 Weight-Loss Drugs Off Shortage List
Here is a rundown of this weeks business news across the valley
Frequent, balanced meals with fiber and fat slow gastric emptying naturally and help stabilize blood sugar, reducing cravings
Mechanism of Action Why Retatrutide Is Called a "Triple Agonist" Investigators classify retatrutide as a triple agonist because the same molecule activates three distinct G-protein-coupled receptors that regulate human metabolism [3][4]
V.KudryavtsevaA
Misuse or overdosing of injectable weight-loss drugs can lead to acute symptoms that may require emergency treatment